Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

Farwell succeeds Jordan Dubow, who will continue to serve as a consultant and chair of the Clinical Advisory Board.

Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's ...

This was the stock's third consecutive day of losses.

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers. Over the next few ...

Fintel reports that on July 14, 2025, Wedbush initiated coverage of Crescent Biopharma (NasdaqCM:CBIO) with a Outperform ...

Biogen Inc. (NASDAQ:BIIB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. In a report released on July 7 ...

TOKYO – Japan is expected to lower the price of lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co.

Biogen Inc. closed 44.11% short of its 52-week high of $238.00, which the company reached on July 12th.

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...